Opioid Rotation in Renal Failure with Refractory Dyspnea
A 71-year-old woman with stage 5 chronic kidney disease (eGFR 9 mL/min/1.73 m², not on dialysis by patient choice) and metastatic lung cancer is admitted with refractory dyspnea. She has been on oral morphine 15 mg every 4 hours for 3 weeks; total daily dose 90 mg. Over the past 48 hours she has become increasingly drowsy between doses, with myoclonic jerks and a respiratory rate of 10/min despite reported ongoing breathlessness. Family asks why she is 'so sleepy yet still gasping.' She is alert enough to state a goal of comfort. Current meds include gabapentin and a benzodiazepine for anxiety.
1. What is the most likely explanation for the combination of sedation, myoclonus, and persistent dyspnea, and how does renal function drive your interpretation?
Read the worked answer
The picture suggests accumulation of morphine metabolites - specifically morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) - in the setting of severe renal impairment. M6G is renally cleared and is a potent mu-agonist, producing sedation and respiratory depression; M3G has been associated with neuroexcitation (myoclonus, hyperalgesia, agitation).
Key reasoning:
- eGFR 9 means glucuronide metabolites are not cleared; toxicity can appear even at 'modest' doses like 90 mg/day.
- Sedation + myoclonus + low respiratory rate is a toxicity pattern, not simply disease progression.
- Persistent dyspnea despite these signs argues the drug is not achieving net benefit and the dose cannot safely be escalated in this formulation.
- The concurrent gabapentin (renally cleared) and benzodiazepine are additive CNS/respiratory depressants and should be reconsidered.
This is not answerable by recall of a single fact - it requires integrating pharmacokinetics, the specific metabolite profile, and the clinical trajectory.
2. Propose a concrete opioid plan, including the rotation calculation logic, monitoring parameters, and how you would counsel the family.
Read the worked answer
Rotation logic (equianalgesic reasoning, not a fixed recipe):
- Current morphine 90 mg/day PO. Standard equianalgesic tables place oral morphine to oral hydromorphone at roughly 5:1 to 7.5:1; using ~5:1 gives ~18 mg/day hydromorphone, but because of incomplete cross-tolerance reduce by 25–50%, landing near 9–12 mg/day.
- In renal failure, hydromorphone is preferred over morphine; its metabolites are less problematic, though still renally cleared. Fentanyl (transdermal or parenteral) is the safest choice in dialysis-independent severe CKD because it has inactive metabolites.
- A defensible plan: stop morphine; start low-dose hydromorphone (e.g., 0.5 mg PO q4h scheduled with q2h breakthrough) or convert to transdermal fentanyl with careful titration, plus a short-acting agent for breakthrough. Avoid codeine and meperidine entirely.
Monitoring: sedation scale (e.g., POSS) before each dose for 24–48 h, respiratory rate, myoclonus, pain/dyspnea scores, and bowel function. Expect improvement in myoclonus within 24–72 h as metabolites clear.
Counseling: explain that the sleepiness and jerking are from drug buildup because her kidneys cannot clear it, that this is not 'the cancer suddenly worsening,' and that we are switching to a drug her body handles better. Reassess the benzodiazepine and gabapentin - both accumulate in renal failure and contribute to sedation. Frame the goal as comfort and alertness together.